<DOC>
	<DOCNO>NCT01015170</DOCNO>
	<brief_summary>Despite significant health , social economic cost cigarette smoking , 17 % Ontarians still currently smoke . Use smoke cessation pharmacotherapy Zyban ( bupropion HCl ) show double quit rate medication under-utilized smoker attempt quit . It suggest high price pharmacotherapy may act barrier access treatment.The main objective study evaluate method effectiveness provide smoker want quit 8 week free Zyban combination smoke cessation counsel family health team community health centre across province . Hypothesis : Ontario smoker receive 8-weeks free bupropion combination brief counsel high smoking cessation rate standard population cessation rate .</brief_summary>
	<brief_title>STOP Study : Effectiveness Zyban Clinical Population</brief_title>
	<detailed_description>Nicotine dependence , like addictive disorder , characterize chronic , relapse disease ( Leshner , 1997 ) . Although significant morbidity mortality associate disorder , majority smoker treat adequately widely accepted goal complete long-term abstinence smoking . This may due under-utilization accepted pharmacotherapies treatment tobacco dependence . Bupropion ( Zyban ) Bupropion first line non-nicotine-based pharmacotherapy smoking cessation . Several large-scale clinical trial show bupropion efficacious smoke cessation aid ( Hurt et al. , 1997 ; Jorenby et al. , 1999 ; Ahluwalia et al. , 2002 ) . In one study , 44 % abstinence rate report seven week treatment bupropion 300 mg/day , compare 19 % placebo ( Hurt et al , 1997 ) . A recent meta-analysis report bupropion monotherapy approximately double rate smoking cessation ( OR 1.94 ) ( Hughes et al , 2007 ) . Despite efficacy , bupropion 's mechanism action unclear . Attenuation abstinence-associated increase crave withdrawal symptom suggest possible mechanisms bupropion 's effect smoking behaviour randomize clinical trial ( Jorneby et al. , 1999 ; Shiffman et al. , 2000 ; Lerman et al. , 2002 ; Durcan et al , 2002 ) . However , effect universally demonstrate ( Hurt et al. , 1997 ; Shiffman et al. , 2000 ) . Other possible bio-behavioral mechanism remain largely unexplored . Using positron emission tomography ( PET ) show contrast untreated smoker , bupropion-treated smoker expose cigarette-related cue less metabolic activation anterior cingulate cortex , region brain previously show activate cigarette cue ( Brody et al. , 2004 ; Brody et al. , 2002 ) . STOP Study Background Rationale Treatment pharmacotherapy nicotine replacement therapy ( NRT ) Zyban safe effective smoking cessation strategy double chance quit successfully long-term ( Cornuz , 2007 ) . However , research show smoker interested quit use pharmacotherapy aid quit attempt . Misconceptions harmful effect nicotine strong barrier use pharmacotherapy . The cost pharmacotherapy may also significant contributor under-utilization smoking cessation aid NRT Zyban . Karnath ( 2001 ) suggest high cost successful pharmacotherapy treatment smoke cessation may barrier individual . Moreover , Cokkinides et al ( 2005 ) report smoker private insurance likely use smoke cessation pharmacotherapies smoker without insurance . The addition free NRT group behavioural cessation program substantiate claim show increase quit rate 38 % 65 % ( Alberg et al , 2004 ) . These study suggest economic barrier may prevent smoker use pharmacotherapy attempt quit smoking . The study propose herein introduce free bupropion another treatment option smoke cessation Ontario smoker . Community Health Centres Aboriginal Health Access Centres interdisciplinary health model able help individual would otherwise prevent access health service due social geographic barrier . As aim eliminate barrier consequently control , ideal health model determine whether eliminate economic barrier smoke cessation improve smoke cessation rate . Family Health Teams recent health model provide integrate interdisciplinary primary health care . Since able treat large diverse population , ideal health model access Ontario smoker . Objectives 1 . To evaluate effectiveness 8-weeks free bupropion combination brief counsel family health team , community health centre aboriginal health access centre Ontario smoke cessation .</detailed_description>
	<mesh_term>Behavior , Addictive</mesh_term>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Ontario resident 18 year age older Current daily cigarette smoker smoke 10 cigarette per day smoke &gt; 100 cigarette lifetime Want quit smoking cigarette within 30 day assessment Willingness capacity give write informed consent comply study protocol Enrollment STOP Study NRT model past 6 month Currently receive Wellbutrin SR medication contain bupropion hydrochloride Current seizure disorder history seizures Current prior diagnosis bulimia anorexia nervosa Current diagnosis bipolar disorder History head trauma Allergy sensitivity Zyban , Wellbutrin bupropion Undergoing abrupt withdrawal alcohol , benzodiazepine sedative Currently take monoamine oxidase ( MAO ) inhibitor , thioridazine Pregnant breastfeeding risk become pregnant Central nervous system ( CNS ) tumor Severe hepatic impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>smoke cessation</keyword>
	<keyword>nicotine addiction</keyword>
	<keyword>Zyban</keyword>
	<keyword>bupropion hydrochloride</keyword>
</DOC>